7
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

      Submit here before May 31, 2024

      About Oncology Research and Treatment: 2.4 Impact Factor I 3.3 CiteScore I 0.495 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Carcinogenic Dose-Related Response to Nitrosamines

      research-article
      Oncology
      S. Karger AG
      Dose response, Dimethylnitrosamine, Diethylnitrosamine, N-nitrosopiperidine, N-nitrosopyrrolidine

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dose-response studies were carried out, principally with dimethylnitrosamine and diethylnitrosamine, in rats. The compounds were given in the drinking water at levels of 33-1,690 ppb, each being given at 15 dose levels. This range of dosage corresponds to approximately 2-1,080 μg/kg b.w./day for male animals and 3-1,470 μg/kg b.w./day for females. Subsidiary experiments using mice and hamsters, and also in rats, where the dialkyl compounds were first given on weaning and at 20 weeks of age were also carried out. In each of these experiments 15 dose levels were used. Additional experiments with N-nitrosopyrrolidine and N-nitrosopiperidine were undertaken. The problems encountered in the experimental design and in the execution of the studies are discussed, and the necessity for pilot studies is emphasized. A preliminary consideration of the results are presented. Lowest levels at which carcinogenic responses were observed were 132 ppb for dimethyl- and diethylnitrosamine in male rats after median survival times in excess of 900 days. Hyperplastic nodules of the liver occurred with dimethyl nitrosamine at a level of 2 , μg/kg b.w./day.

          Related collections

          Author and article information

          Journal
          OCL
          Oncology
          10.1159/issn.0030-2414
          Oncology
          S. Karger AG
          978-3-8055-1137-7
          978-3-318-01737-3
          0030-2414
          1423-0232
          1980
          1980
          10 June 2009
          : 37
          : 4
          : 251-254
          Affiliations
          Departamento de Farmacologia y Toxicologia, Centro de Investigatión del 1PN, Mexico
          Article
          225446 Oncology 1980;37:251–254
          10.1159/000225446
          7443156
          b4830f1f-8465-4867-b177-8ddd73976b10
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 4
          Categories
          Risk Assessment of N-Nitroso Compounds for Human Health

          Oncology & Radiotherapy,Pathology,Surgery,Obstetrics & Gynecology,Pharmacology & Pharmaceutical medicine,Hematology
          N-nitrosopiperidine,N-nitrosopyrrolidine,Diethylnitrosamine,Dose response,Dimethylnitrosamine

          Comments

          Comment on this article